Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Business Exposures
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
The Benefits of Genetic Testing for Patients with CDKL5 Deficiency Disorder and Other Rare Genetic Epilepsies
Via Brandpoint
Exposures Product Safety
Ford Recalls Over 37,000 Vehicles, Including Mustang Mach-E EV SUV, Due To Non-Operational Front Windshield Wipers
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Tickers F
Custics Singapore’s Hautuki Arrives at Incheon International Airport Duty-Free Shop
Via Binary News Network
Exposures Product Safety
Advanced Hood Cleaning Solutions Enhances Commercial Kitchen Safety with Comprehensive Cleaning and Maintenance Services
Via Get News
Exposures Product Safety
MDMA Therapy Papers Retracted Amid Ethical Concerns At Lykos Study Site
Via Benzinga
Exposures Product Safety
FDA Backs Off Joint Study On Kratom And Psychedelics Amidst Public Criticism
Via Benzinga
Exposures Product Safety
Steven Gillhouse Featured in Exclusive Interview on Ideamensch
Via Get News
Topics Product Recall
Exposures Legal Product Safety
Electrically Altering Children's Brains: Psychiatry's Latest Treatment Fad
Via PRLog
Exposures Product Safety
Electrically Altering Children’s Brains: Psychiatry’s Latest Treatment Fad
Via Press Release Distribution Service
Exposures Product Safety
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Holds Initial Breakthrough Therapy Meeting with FDA, Plans for CYB003 Phase 3 Trial
Via Investor Brand Network
Exposures Product Safety
Tickers CYBN
GM Recalls Nearly 22,000 Cadillac Lyriq Electric SUVs Due To Concerns About Loss Of Braking Ability
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Tickers GM
Shock-Gard CEO Matthew Bullock: Driving Innovation from Philadelphia to Miami
Via Zexprwire
Topics Product Recall
Exposures Legal Product Safety
CCHR Commends FDA Decision: Psychedelic Drug Ecstasy Not Proven Safe or Effective Treatment for Traumatized Patients
Via Press Release Distribution Service
Exposures Product Safety
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
Via Benzinga
Exposures Product Safety
Tickers ASND TAK
Hautuki Introduces Safe and Easy Supplements: Skin-Friendly, Hassle-Free Patch Solutions
Via AB Newswire
Exposures Product Safety
Hautuki, Safe and Easy Supplements: Gentle on Skin, Hassle-Free Patch
Via AB Newswire
Exposures Product Safety
New Study Reveals How Classical Music Could Revolutionize Depression Care
Via PressReach
Exposures Product Safety
Tickers ALZN AXSM BIIB NBIX
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder
Via PressReach
Exposures Product Safety
Tickers ALZN
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder
Via PressReach
Exposures Product Safety
Tickers ALZN
Ascendis Pharma Zips Higher After FDA Approves Embattled Thyroid Drug
Via Investor's Business Daily
Exposures Product Safety
Tickers ASND
Delay Hits Humacyte's Bioengineered Human Tissue Implant For Vascular Trauma Injuries, FDA Extends Time To Review
Via Benzinga
Exposures Product Safety
Tickers HUMA
Heart Failure-Focused scPharmaceuticals Secures FDA Approval For Expanded Use Of Furoscix, Receives Funding To Expand Commercialization
Via Benzinga
Exposures Product Safety
Tickers SCPH
The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
Via Newsfile
Exposures Product Safety
Tickers AEMD NVS
Adaptimmune Reports Q2 2024 Financial and Business Updates
Via Newsfile
Exposures Product Safety
Tickers ADAP
FDA Breakthrough Device That Can Reverse Alzheimer’s Cognitive Decline May Well Increase Human Life Span
Via Get News
Exposures Product Safety
FDA Rejects MDMA For PTSD Treatment, Calls For More Research On Psychedelic Therapy
Via Benzinga
Exposures Product Safety
American Kratom Association Welcomes the FDA Withdrawal of Deeply Flawed Risk/Safety Data Collection and Study on Psychedelic and Kratom Use
Via EZ Newswire
Exposures Product Safety
FDA Poised To Make Historic Decision On MDMA Therapy To Treat PTSD: Here's How Things Stand
Via Benzinga
Exposures Product Safety
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
Via Benzinga
Exposures Product Safety
Tickers SNY SPRY
Analysis Shows Recalls Woefully Slow in Removing Potentially Contaminated Cannabis from Circulation
Via CannabisNewsWire
Topics Cannabis Product Recall
Exposures Cannabis Legal Product Safety
Tickers VRNOF
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.